A solid tumor next-generation sequencing assay for biomarker analysis

The Oncomine™ Focus Assay is a targeted, multi-biomarker assay that enables simultaneous detection of thousands of variants across 52 genes relevant to solid tumors.  Designed for translational and clinical research, this assay includes solid tumor genes targeted by on-market oncology drugs and published evidence.  This assay enables you to get results from up to 6 samples per run for DNA and RNA in a single workflow.

  • Intelligent content design:
    • Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA and RNA in a single workflow
    • Content driven by the Oncomine™ Knowledgebase, which includes content aligned to approved therapies and indications
  • Sensitive tumor analysis: enables detection using low-input FFPE samples such as fine needle biopsies and core needle aspirates, so you can get results with more of your samples
  • Quick path to results: easy-to-perform workflow with fast turnaround time enables you to get your NGS data in days instead of weeks

Discuss the Oncomine Focus Assay and Ion PGM™ System with a member of our clinical research team:

Request to be contacted

Oncomine Focus Assay Workflow

Oncomine Focus™ Assay Workflow

The Oncomine Focus Assay workflow enables you to get robust results with your FFPE samples, including precious fine needle aspirates and needle biopsies. Leveraging the power of Ion AmpliSeq™ technology, this highly multiplexed NGS assay enables you to produce RNA and DNA results in a single run.  Designed for use on the Ion PGM System, results are delivered in days rather than weeks.

The resulting annotated variant data, including hotspots, CNVs, indels, and gene fusions, can be further analyzed using the Oncomine™ Knowledgebase Reporter, which helps users prepare a report meeting their specific laboratory needs.

Discuss the Oncomine Focus Assay and Ion PGM System with a member of our clinical research team:

Request to be contacted

file

The Oncomine Focus Assay is a solid tumor NGS assay optimized for routine biomarker analysis.

Intelligent content design:

  • Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA and RNA in a single workflow
  • Designed for translational and clinical research, includes 52 genes targeted by on-market oncology drugs and published evidence
  • Content design driven by the Oncomine Knowledgebase, the world’s largest curated compendium of cancer genomic information

Sensitive tumor analysis:

  • Powered by proven Ion AmpliSeq™ technology, which enables detection using low-input FFPE samples such as fine needle biopsies and core needle aspirates
  • As little as 10 ng DNA or RNA/pool, or 3-4 FFPE slides required for reliable results

Quick path to results

  • Easy-to-perform workflow with fast turnaround time enables you to get your NGS data in days instead of weeks
  • Highly multiplexed solution enables results from up to six samples per run

Quality performance

  • Includes Ion Select consumables and reagents, lot matched and manufactured to rigorous standards in our ISO 13485 compliant facility

Discuss the Oncomine Focus Assay and Ion PGM System with a member of our clinical development team:

Request to be contacted

file

Features of the Ion PGM System include:

  • Reliable results with minimal sample input from FFPE material (as little as 10 ng/pool)
  • Turnaround times aligned with clinical research needs
  • Analysis of hundreds of genes in a single run

The Ion PGM System combines semiconductor sequencing technology with natural biochemistry to directly translate chemical information into digital data. This eliminates the need for complicated optics and detection systems, making it accessible to virtually any laboratory. Real-time sequence detection speeds you to results, taking you from sample to annotated results in 3 days.

Discuss the Oncomine Focus Assay and Ion PGM System with a member of our clinical development team:

Request to be contacted

Oncomine Knowledgebase Reporter data tables and reported summaries

To inform and drive drug discovery and companion diagnostic development programs, the vast genomic data sets produced by next-generation sequencing studies must be analyzed, annotated, and ultimately interpreted by experienced bioinformaticians. The Oncomine Knowledgebase, the world’s largest curated compendium of cancer genomic information, is a database of integrated cancer genomics data with exceptional attention to detail. The Oncomine Knowledgebase was an instrumental tool in the selection of targets for and the development of the Oncomine™ Comprehensive Assay and the Oncomine Focus Assay.

Powered by the Oncomine Knowledgebase, the Oncomine™ Knowledgebase Reporter was developed specifically for further examination of next-generation sequencing data generated from samples analyzed using the Oncomine Comprehensive Assay. Users may subsequently use this information to create data summaries and reports appropriate for their needs.

The Oncomine Knowledgebase Reporter is a curated set of published evidence from clinical trials that supports the matching of driver genetic variants with relevant potential clinical therapeutic options, such as published therapeutic interventions and clinical trials. The Oncomine Knowledgebase Reporter is comprised of two component tools:

  • Oncomine Knowledgebase Reporter data tables
    • 3 data lookup tables in tab separated (.TSV) file format
    • Oncomine™ driver, prevalence, and potential actionability  for individual variants
  • Oncomine Knowledgebase Reporter reported summaries
    • Pre-rendered supplementary information tables in PDF format
    • Summary files for variant potential actionability class and cancer type

Discuss the Oncomine Focus Assay and Ion PGM System with a member of our clinical research team:

Request to be contacted